Aurobindo Pharma developing products to expand portfolio in US, EU markets

Currently, five products are under development, out of which the first two products would be filed towards the end of this year or early next year

Drug major Aurobindo Pharma is developing a range of products including 14 biosimilars as it looks to expand its product portfolio in the US and EU markets, according to a top company official.

The firm is developing eight inhalers and six nasal sprays, out of which two products have already been filed, Aurobindo Pharma Managing Director N Govindarajan said in an analyst call.

He was responding to a query on company's product pipeline for the US market.

"As far as the topicals are concerned, 37 products are in the pipeline at various stage of development and we are developing eight